A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-27

Study Completion Date

2024-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically.

Participants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

NCT04876365

Hemophilia A

COMPLETED

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

NCT04565236

Hemophilia A

COMPLETED PHASE4

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

NCT02634723

Hemophilia A

COMPLETED

China ADVATE PTP Study

NCT02170402

Hemophilia A

COMPLETED PHASE4

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934

Hemophilia A

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adynovate 45±5 IU/kg

Participants received prophylactic treatment with Adynovate (45 \[±5\] IU/kg), infusion, IV, twice weekly, for at least 50 EDs, or approximately 28 weeks.

Group Type EXPERIMENTAL

Adynovate

Intervention Type BIOLOGICAL

Adynovate was injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adynovate

Adynovate was injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant and/or legally authorized representative must voluntarily sign a written informed consent form (ICF) after all relevant aspects of the study have been explained and discussed with the Participant. For the participants less than (\<) 18 years old, participants will give assent AND their parents/legally authorized representative should sign the ICF accordingly.
2. Participant and/or legally authorized representative understands and is willing and able to comply with all requirements of the study protocol.
3. Participant should be ethnic Chinese.
4. Participant is 12 to 65 years of age at screening and male.
5. Participant has severe hemophilia A (FVIII clotting activity \<1 percent \[%\]) as confirmed by the central laboratory at screening after a washout period of at least 72 to 96 hours.
6. The last on-demand or prophylactic treatment received is within 3 months before screening.
7. Participant has documented previous treatment with plasma-derived FVIII concentrates or recombinant FVIII for greater than (\>) 150 EDs.
8. Participant is human immunodeficiency virus (HIV)-negative, or HIV-positive with stable disease and CD4+ count greater than or equal to (\>=) 200 cells per cubic millimeter (/mm\^3).
9. Participant is hepatitis C virus (HCV) negative by antibody testing (if positive, additional polymerase chain reaction testing will be performed to confirm), as confirmed at screening; or HCV-positive with chronic stable hepatitis, as assessed by the investigator.

Exclusion Criteria

1. Participant has detectable FVIII inhibitory antibodies (\>=0.6 Bethesda units \[BU\] per milliliter \[/mL\] using the Nijmegen modification of the Bethesda assay) as confirmed by the central laboratory at screening.
2. Participant has a confirmed history of FVIII inhibitory antibodies (\>=0.6 BU using the Nijmegen modification of the Bethesda assay or \>=0.6 BU using the Bethesda assay) at any time prior to screening.
3. Participant has a known hypersensitivity to Adynovate or ADVATE or any of the components of the study drugs, such as mouse or hamster proteins, or other FVIII products.
4. Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (example, qualitative platelet defect or von Willebrand's disease).
5. Participant has severe hepatic dysfunction (example, \>=5 times the upper limit of normal \[ULN\] for alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\], a recent or persistent international normalized ratio \[INR\] \>1.5, as confirmed by the local laboratory at screening).
6. Participant has severe renal impairment (serum creatinine \>1.5 times the ULN) as confirmed by the local laboratory at screening.
7. Participant is planned or likely to undergo major surgery during the study period.
8. Participant has current or recent (\<30 days) use of other PEGylated drugs before study participation or scheduled use of such drugs during study participation.
9. Participant has received emicizumab therapy within 6 months of screening.
10. Participant is currently receiving, or scheduled to receive during the study, an immunomodulating drug (example, systemic corticosteroid agent at a dose equivalent to hydrocortisone \>10 milligram per day \[mg/day\], or alpha-interferon) other than antiretroviral chemotherapy.
11. Participant has participated in another clinical study involving the use of an investigational product (IP) other than Adynovate or an investigational device within 30 days before the screening visit or is scheduled to participate in another clinical study involving an IP or investigational device during this study.
12. Participant has a medical, psychiatric, or cognitive illness or recreational drug/alcohol use that, in the opinion of the investigator, would affect participant safety or compliance.
13. Participant, in the opinion of the investigator, is unable or unwilling to comply with the study protocol.

Minimum Eligible Age

12 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No